Global

‡ In these countries please contact our distributor

Expand in Emerging & International Markets

We will deliver market leadership in the Emerging & International Markets by building strong, direct customer relationships and developing products specifically designed for these populations.

("Emerging & International Markets" represent those outside of the Established Markets including Brazil, China, India and Russia.)

Performance

The Emerging & International Markets grew at 18% during 2013, exceeding Established Markets rates and contributing half of annual revenue growth for the Group. These geographies now represent 13% of the Group’s overall revenue.

Revenue from Emerging and International Markets1

+18%  $563m

As a percentage of group revenue

13%

During 2013:

  • Our success in China continued with growth of over 30% and now it is our 6th largest country by revenue
  • Significant investment to drive growth organically (e.g. Mexico and Saudi Arabia) and through acquisitions (Brazil, Turkey, India)
  • We put in place our strategy to address the mid-tier market.

Global outlook

The healthcare environment in these markets is rapidly expanding and with the right investments offers significant opportunities for the Group.

 

Notes

2011 includes Clinical Therapies revenue of $237m
2012 includes Clinical Therapies revenue of $107m
1 The underlying percentage increases/decreases are after adjusting for the effect of currency translation and the inclusion of the comparative impact of acquisitions and exclusion of disposals.
2 Explanations of these non-GAAP financial measures are provided on pages 161 to 163 of our 2013 Annual Report.